News & Videos - AVACTA GRP. ORD 10P

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona LONDON – Oct. 24, 2024 – Avacta Therapeutics (AIM: AVCT) , a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces scientific presentations of two novel programs in its pipeline at the 2024 EORTC-NCI-AACR...

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology LONDON – Oct. 21, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the initiation of an artificial intelligence (AI)-focused collaboration with Tempus AI, Inc. (Nasdaq: TEM), a technology...

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION ® Platform London, Oct. 17, 2024 – Avacta Group plc (AIM: AVCT) , a life sciences company developing innovative targeted oncology drugs, today announces the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION ® -enabled drug conjugates. Avacta is developing a portfolio of pre|CISION ® product candidates...

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer London, Oct. 15, 2024 – Avacta Group plc (AIM: AVCT) , a life sciences company developing innovative, targeted oncology drugs, today announced the appointment of seasoned scientific leader Michelle Morrow, PhD as Chief Scientific Officer with effect from November 4, 2024. Dr. Morrow brings nearly 20 years’ experience in...

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer London, Oct. 15, 2024 – Avacta Group plc (AIM: AVCT) , a life sciences company developing innovative, targeted oncology drugs, today announced the appointment of seasoned scientific leader Michelle Morrow, PhD as Chief Scientific Officer with effect from November 4, 2024. Dr. Morrow brings nearly 20 years’ experience in...

10 October 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium LONDON, UK, 10 OCT 2024, Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION™ platform in poster sessions at the 2024...

10 October Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium LONDON, UK, 10 OCT 2024, Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION™ platform in poster sessions at the 2024...

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 14 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta Reports Updated Phase 1...

8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated data from the Phase 1a trial of AVA6000 at the 2024 European Society for Medical Oncology (ESMO) Congress, in...

Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT) , a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company’s Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial...

5 April 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the American Association of Cancer Research (“AACR”) Annual Meeting in San Diego, California on Tuesday 9 April has now been released by AACR. The poster...

5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the...

19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical progress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division. Simon has over 26 years’ commercial experience...

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 13 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) ALS-6000-101 Phase 1a Three-Weekly...

5 October 2023 Avacta Group plc (“Avacta” or the “Group” or the “Company”) Avacta to present promising new data from Affimer® and pre|CISION TM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics AVA3996: FAP-α-activated proteasome inhibitor from pre|CISION TM platform concentrates proteasome inhibitor payload in the tumour, increasing the therapeutic index of this class of drugs AVA032: anti-PD-L1 Affimer ® fused to IL-15...

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully. The data continue to show a very favourable safety profile for the tumour targeted chemotherapy and several patients in cohort 5 and earlier cohorts remain on treatment as...

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safety and tolerability of AVA6000, a novel tumour targeted form of doxorubicin and Avacta’s first therapeutic product based on its proprietary pre|CISION™ technology. The first patient in the US has...

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer of its Therapeutics Division. In her new role, Karen will be responsible for supporting the research and development functions across Avacta’s Therapeutics Division, with her focus exclusively on creating maximum value for the Group’s stakeholders. Latest clinical data for the Company’s...

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma. AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is...

Avacta receives more support after cancer drug progress It's been another day of gains for #AVCT stock, this time as LG Chem ......